Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...
The patchwork rollout of a gene therapy exposes weaknesses in the pricing and regulatory frameworks that determine who ...
FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and ...
The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...
Swiss pharmaceutical giant Novartis AG (NYSE:NVS) has entered into a massive $1.7 billion partnership with British ...
DURHAM, N.C. (WTVD) -- Global drugmaker, Novartis, is committed to North Carolina by expanding in three sites in the Research ...
Citius Oncology entered into an exclusive distribution agreement with Er-Kim to expand international access to Lymphir (denileukin diftitox-cxdl) in Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia ...
A Swiss drugmaker is breaking ground on new buildings in Durham. Novartis plans to spend hundreds of millions of dollars in ...
Pharmaceutical Technology on MSN
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn
"Novartis and UK-based Relation forge R&D deal worth up to $1.7bn" was originally created and published by Pharmaceutical ...
A Swiss drugmaker is breaking ground on new buildings in Durham. Novartis plans to spend hundreds of millions of dollars in ...
At this year’s American College of Allergy, Asthma & Immunology Scientific Meeting, Anne K. Ellis, MD, MSc, FACAAI, received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback